Eli Lilly to be among top 20 pharma firms in India by 2020
The company is looking at launching more innovation-based products in India.
New Delhi, January 21, 2014: Eli Lilly and Co India is aiming to become part of the top 20 pharma firms in India by 2020. The company is looking at introducing more innovation based products across the five therapeutic segments, including diabetes, over the next six years.
The company has recently launched an insulin delivery pen, HumapenSavvio, and it currently stands at the 47th position in terms of revenues in the Indian pharmaceutical industry.
It may be noted here that the company is putting maximum focus on the diabetes portfolio and plans to launch more new products to cater to over 60 million patients in India.
The company also has presence in the osteoporosis, cardiovascular, oncology and growth hormones segments, apart from the diabetes segment.